Total amount: € 0,00
Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752
Online ISSN 1827-1618
INTENSIVE CARDIAC CARE - PART II
Tamburino C., Immè S., Barbanti M., Mulè M., Pistritto A. M., Aruta P., Cammalleri V., Scarabelli M., Mangiafico S., Scandura S., Ussia G. P.
1 Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy;
2 Excellence Through Newest Advances (ETNA) Foundation, Catania, Italy
Mitral regurgitation (MR) is the second most common heart valve disease worldwide and the current gold-standard treatment is surgical repair or replacement. Nevertheless, many patients do not undergo surgical intervention due to several comorbidities. Percutaneous “edge-to-edge” mitral valve repair using the MitraClip System is an emerging and effective option to this subset of patients. This device has been used to treat both functional and degenerative mitral valve regurgitation and has been compared to surgery in the Endovascular Valve Edge-to-Edge Repair Study II (EVEREST II) randomized trial. Although the field of percutaneous management of MR is at an early stage, it has been demonstrated that percutaneous approaches can reduce MR, suggesting there is a great deal of potential for clinical benefit to patients with MR.